For more information or to enroll in one of these trials, call our Largo (Pinellas County) Clinical Research Department at 727-441-1508 ext 119.
Clinical Trials
Staying at the Forefront Through Clinical Research
Home
/ Clinical Trials
The newest treatment advances come through clinical research trials. By conducting these research trials, our patients have access to expert knowledge and promising treatments before they are widely available.
Your participation means you’ll receive regular and careful medical attention from AUI research teams including urologists and other medical specialists. And you’ll play an important role in advancing medicine.
Clinical Trial Sponsors
Partner with AUI for your next Clinical Research Trial. For details, call the number listed for each location.
Clinical Research Trials at AUI
Every clinical research trial described below follows strict guidelines to ensure your safety. Ask your doctor if there’s a trial that is right for you. Or call the number listed at the end of the group of trial descriptions for each location.
Daytona Region
Clinical trials for patients with Bladder Cancer:
STM-416-01
SURGE Therapeutics
A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer
CRETO-EAP
CG-Oncology
An Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Clinical trials for patients with Overactive Bladder (OAB):
Sacral Neuromodulation for Male OverActive Bladder (MOAB) Study
Boston Scientific Corporation (Axonics)
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s) for the treatment of overactive bladder in male patients who have a prior history of radical prostatectomy or radiation for prostate cancer or who have a history of cytoreductive surgical intervention for benign prostatic hyperplasia (BPH).
Clinical trials for patients with Prostate Cancer:
Dendreon P23-1
Dendreon Pharmaceuticals
NCT06134232
An Open-Label, Multicenter Study of Subjects with Metastatic Castrate-Resistant Prostate Cancer Treated with Provenge and Boosted with a Single Infusion of Sipuleucel-T to Measure Immune Response.
Oxford Region
Clinical trials for patients with Prostate Cancer:
Dendreon P23-1
Dendreon Pharmaceuticals
NCT06134232
An Open-Label, Multicenter Study of Subjects with Metastatic Castrate-Resistant Prostate Cancer Treated with Provenge and Boosted with a Single Infusion of Sipuleucel-T to Measure Immune Response.
Pinellas Region
Clinical trials for patients with Bladder Cancer:
CORE-008
G Oncology, Inc.
NCT06567743
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with Carcinoma In Situ. All patients with CIS are eligible. We will soon be able to include BCG refractory patients. We will let you know as soon as this arm in the study opens. Please counsel patients on the study at the time of the path review and send a Jellybean to Amy Franklin for review.
Clinical trials for patients with Prostate Cancer:
Ortho A&S
QuidelOrtho
Demonstrate higher % fPSA [(VITROS Free PSA III/ VITROS Total PSA III) x 100] is associated with lower probability of prostate cancer in subjects 50 years of age or older evaluated for prostate cancer that have prostate biopsy results, a total PSA value in the range of 4.0 to 10.0 ng/mL and DRE findings not suspicious for cancer. The VITROS Immunodiagnostic Products Free PSA III assay is for the quantitative measurement of free PSA in human serum and plasma using the VITROS 3600 Immunodiagnostic System, VITROS 5600 Integrated System and VITROS XT 7600 Integrated System.
IsoPSA
Cleveland Diagnostics, INC
CDx2023-01B
A Non-Randomized Single-Blind Multi-Site Study for Supplemental Clinical Validation of the IsoPSA Assay in African Americans The IsoPSA® Assay is a diagnostic test system that evaluates total and free Prostate Specific Antigen (PSA) in IsoPSA Reagent-partitioned heparinized plasma samples and reports a single numerical score.
Dendreon P23-1
Dendreon Pharmaceuticals
NCT06134232
An Open-Label, Multicenter Study of Subjects with Metastatic Castrate-Resistant Prostate Cancer Treated with Provenge and Boosted with a Single Infusion of Sipuleucel-T to Measure Immune Response.